Guidance Document on the Use of Pandemic Influenza A (H1N1) 2009 Inactivated Monovalent Vaccine

UPDATE ON DOSING RECOMMENDATIONS FOR CHILDREN: H1N1 FLU VACCINE

This update on dosing recommendations is based on current evidence which points to very low levels of pandemic H1N1 flu activity across Canada:

Children older than six months and under the age of three years and children between the ages of three and nine years with chronic health conditions who have already received a single half-dose of H1N1 flu vaccine do not require a second dose at this time as the H1N1 flu virus is not presently circulating.

Revised November 20, 2009

[Next]

Table of Contents

1. Preamble
2. Introduction
3. Epidemiology
4. Preparations Approved for Use in Canada
5. Immunogenicity and Efficacy
   • Adults
   • Children
   • Older adults
   • Pregnant women
6. Recommendations for Use of Influenza A (H1N1) 2009 Vaccine
7. Recommended Recipients
   • Persons at higher risk of complications from pH1N1 and those who care for them
   • Other groups that can benefit from pandemic influenza vaccine.
8. Schedule and Dosage
   • Recommended dosage schedule
   • Persons who have had pH1N1 infection or influenza-like illness
9. Choice of Product
   • Pregnant women
   • Children aged 6 months to 9 years
   • Persons aged 10 to 64 years
   • Persons aged 65 years and above
10. Route of Administration
11. Adverse Reactions
    • Vaccines containing the AS03 adjuvant
    • GSK H5N1 adjuvanted vaccines
    • GSK pH1N1 vaccines
    • MF59-adjuvanted influenza vaccines
    • Other considerations
12. Contraindications
13. Precautions
14. Simultaneous Administration of Other Vaccines
15. Storage and Reconstitution
16. Research and Evaluation Priorities

17. References

    Appendix: Schema for ranking individual study design – National Advisory Committee on Immunization

[Next]